Two real-world studies published in The New England Journal of Medicine draw conflicting conclusions on the effectiveness of treatment regimens involving intravenous immunoglobulin and glucocorticoids for the treatment of multisystem inflammatory disease in children.
Add-on treatment with the JAK inhibitor tofacitinib reduces the risk for death or respiratory failure among hospitalized patients with COVID-19 pneumonia who are not receiving mechanical ventilation, shows the STOP-COVID trial.
The majority of patients with systemic lupus erythematosus and confirmed COVID-19 are able to produce a durable antibody response to the infection, despite the use of immunosuppressants, US research suggests.
A pooled analysis of data from the SELECT-PsA-1 and SELECT-PsA-2 trials suggests that treatment with the JAK inhibitor upadacitinib improves axial symptoms in patients with psoriatic spondylitis.
Further research confirming an association between rituximab and an increased risk for severe COVID-19 was reported at the EULAR 2021 Virtual Congress.
Findings from two real-world studies presented at the EULAR 2021 Virtual Congress suggest that JAK inhibitors and biologics are similarly effective for the treatment of inflammatory arthritis.
A Mendelian randomization analysis presented at the EULAR 2021 Virtual Congress suggests that the association between gout and hypertension may have a causal basis.
Inhibition of GM-CSF with mavrilimumab may represent a promising treatment option for patients with severe COVID-19 pneumonia and systemic hyperinflammation, suggest phase 2 study results.
Children and adolescents with juvenile psoriatic arthritis or enthesitis-related arthritis may benefit from treatment with the IL-17A inhibitor secukinumab, indicate phase 3 study results.
Initial data from the COVAX Registry offer reassurance for patients with rheumatic and musculoskeletal diseases that adverse events with the COVID-19 vaccines are similar to those seen in the general population.
Allopurinol and benzbromarone have comparable cardiovascular risk profiles in patients with gout, suggests research presented in a poster at the EULAR 2021 Virtual Congress.
Researchers have found that children and young people with juvenile idiopathic arthritis can be categorized into five different groups according to their response to etanercept treatment.
The addition of levilimab to methotrexate improves response rates among patients with rheumatoid arthritis who are resistant to methotrexate, show phase 3 SOLAR data presented in a poster at the EULAR 2021 Virtual Congress.